VIVES is a multi-sector fund that invests in projects with a positive societal impact
Generare is unlocking nature’s untapped potential, turning the complexity of microbial DNA into a scalable platform that can transform drug discovery.
By combining advanced biotechnology with data...
Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.
With the...
Viridaxis is a specialist in development and supply of efficient and effective natural aphid control methods for the agricultural sector. Their R&D activities include applied field research to...
David Frenay, CEO Emolytics:
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Pierre-Antoine Mariage, co-CEO Botalys:
"VIVES trusted us at an early stage. In addition to their financial investment, they offer us a regular and wise coaching from their experts while respecting...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to